Please use this identifier to cite or link to this item:
Title: Combined effects of smoking and HPV16 in oropharyngeal cancer.
Authors: Anantharaman, Devasena
Muller, David C
Lagiou, Pagona
Ahrens, Wolfgang
Holcátová, Ivana
Merletti, Franco
Kjærheim, Kristina
Polesel, Jerry
Simonato, Lorenzo
Canova, Cristina
Castellsague, Xavier
Macfarlane, Tatiana V
Znaor, Ariana
Thomson, Peter
Robinson, Max
Conway, David I
Healy, Claire M
Tjønneland, Anne
Westin, Ulla
Ekström, Johanna
Chang-Claude, Jenny
Kaaks, Rudolf
Overvad, Kim
Drogan, Dagmar
Hallmans, Göran
Laurell, Göran
Bueno-de-Mesquita, H B
Peeters, Petra H
Agudo, Antonio
Larrañaga, Nerea
Travis, Ruth C
Palli, Domenico
Barricarte, Aurelio
Trichopoulou, Antonia
George, Saitakis
Trichopoulos, Dimitrios
Quirós, J Ramón
Grioni, Sara
Sacerdote, Carlotta
Navarro, Carmen
Sánchez, María-José
Tumino, Rosario
Severi, Gianluca
Boutron-Ruault, Marie-Christine
Clavel-Chapelon, Francoise
Panico, Salvatore
Weiderpass, Elisabete
Lund, Eiliv
Gram, Inger T
Riboli, Elio
Pawlita, Michael
Waterboer, Tim
Kreimer, Aimée R
Johansson, Mattias
Brennan, Paul
Keywords: Human papillomavirus;head and neck cancer risk;interaction;oropharynx cancer;tobacco smoking
metadata.dc.subject.mesh: Adult
Antibodies, Viral
Bayes Theorem
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Human papillomavirus 16
Logistic Models
Middle Aged
Odds Ratio
Oropharyngeal Neoplasms
Papillomavirus Infections
Risk Factors
Tobacco Smoking
Issue Date: 19-May-2016
Abstract: Although smoking and HPV infection are recognized as important risk factors for oropharyngeal cancer, how their joint exposure impacts on oropharyngeal cancer risk is unclear. Specifically, whether smoking confers any additional risk to HPV-positive oropharyngeal cancer is not understood. Using HPV serology as a marker of HPV-related cancer, we examined the interaction between smoking and HPV16 in 459 oropharyngeal (and 1445 oral cavity and laryngeal) cancer patients and 3024 control participants from two large European multi-centre studies. Odds ratios and credible intervals [CrI], adjusted for potential confounders, were estimated using Bayesian logistic regression. Both smoking [odds ratio (OR [CrI]: 6.82 [4.52, 10.29]) and HPV seropositivity (OR [CrI]: 235.69 [99.95, 555.74]) were independently associated with oropharyngeal cancer. The joint association of smoking and HPV seropositivity was consistent with that expected on the additive scale (synergy index [CrI]: 1.32 [0.51, 3.45]), suggesting they act as independent risk factors for oropharyngeal cancer. Smoking was consistently associated with increase in oropharyngeal cancer risk in models stratified by HPV16 seropositivity. In addition, we report that the prevalence of oropharyngeal cancer increases with smoking for both HPV16-positive and HPV16-negative persons. The impact of smoking on HPV16-positive oropharyngeal cancer highlights the continued need for smoking cessation programmes for primary prevention of head and neck cancer.
metadata.dc.identifier.doi: 10.1093/ije/dyw069
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.